Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort Study:Uptake, Outcome, and Risk Factors for Treatment Failures
NCT ID: NCT06405464
Last Updated: 2024-05-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
600 participants
OBSERVATIONAL
2022-03-01
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Two Different Formulations of Long-acting Cabotegravir in Healthy Adult Participants
NCT06033547
Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers
NCT02478463
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
NCT06741397
Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants
NCT04484337
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
NCT05418868
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Swiss HIV Cohort Study participants on CAB+RPV LA regimen
Swiss HIV Cohort Study participants initiating the CAB+RPV LA regimen
VOCABRIA 30Mg Tablet
CAB 30 mg Film-coated tablets
EDURANT 25Mg Tablet
RPV 25 mg film-coated tablets
Cabotegravir Injectable Suspension
CAB LA 600 mg prolonged release suspension for injection (3 mL)
Rilpivirine Injectable Suspension
RPV LA 900 mg prolonged release suspension for injection (3 mL)
Intact proviral DNA assay
HIV-1 latent reservoir size
Full-length sequencing
Proviral DNA
Swiss HIV Cohort Study participants on a standard of care oral regimen
Matched control population on a standard of care oral regimen
Intact proviral DNA assay
HIV-1 latent reservoir size
Full-length sequencing
Proviral DNA
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
VOCABRIA 30Mg Tablet
CAB 30 mg Film-coated tablets
EDURANT 25Mg Tablet
RPV 25 mg film-coated tablets
Cabotegravir Injectable Suspension
CAB LA 600 mg prolonged release suspension for injection (3 mL)
Rilpivirine Injectable Suspension
RPV LA 900 mg prolonged release suspension for injection (3 mL)
Intact proviral DNA assay
HIV-1 latent reservoir size
Full-length sequencing
Proviral DNA
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* All SHCS participants initiating the CAB+RPV LA regimen
* All SHCS participants on SOC oral regimen
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Swiss HIV Cohort Study
NETWORK
University of Zurich
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jessy J Duran Ramirez, MSc
Role: PRINCIPAL_INVESTIGATOR
Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Zurich
Zurich, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
222485
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
903_SHCS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.